Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953912 | 0.84 | SRC (0.36) | SRCCYP2A6ALDH1A1LMNAPOLB | |
| SCHEMBL31039285 | 0.84 | ALDH1A1 (0.38) | SRCCYP2A6ALDH1A1LMNAPOLB | |
| SCHEMBL18266291 | 0.84 | NOS2 (0.52) | SRCCYP2A6ALDH1A1NOS3NOS1 | |
| SCHEMBL29951624 | 0.84 | SRC (0.40) | SRCCYP2A6ALDH1A1LMNAHTT | |
| SCHEMBL1043931 | 0.84 | ALDH1A1 (0.38) | SRCCYP2A6ALDH1A1LMNAPOLB | |
| SCHEMBL12990369 | 0.84 | SRC (0.36) | SRCCYP2A6ALDH1A1LMNAPOLB | |
| SCHEMBL31039438 | 0.84 | SRC (0.36) | SRCCYP2A6ALDH1A1LMNAPOLB | |
| SCHEMBL2746692 | 0.80 | NOS3 (0.38) | SRCCYP2A6ALDH1A1LMNANOS3 | |
| SCHEMBL1619663 | 0.80 | CYP1A2 (0.41) | SRCCYP2A6ALDH1A1LMNAPOLB | |
| SCHEMBL21715686 | 0.80 | NOS3 (0.38) | SRCCYP2A6ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6288091-B1 | COMPOUNDS SUCH AS 2,2,2-TRICHLOROETHYL N-(4-(2-AMINO-4-THIAZOLYL)-PHENYL)CARBAMATE THAT INHIBIT THE HERPES HELCASE-PRIMASE ENZYME COMPLEX | BOEHRINGER INGELHEIM LTD. (CA) | 2001-09-11 | — | — | US | claimed |
| EP-4126835-B1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-12516038-B2 | Inhibitors of antigen presentation by HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-01-06 | — | — | US | disclosed |
| US-20250313561-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2025-10-09 | — | — | US | disclosed |
| US-12421224-B2 | Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12344606-B2 | Next-generation modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2025-07-01 | — | — | US | disclosed |
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-05-30 | — | — | US | disclosed |
| CN-117355303-A | Compounds and their use for the treatment of neurodegenerative, degenerative and metabolic disorders | 佛罗里达大学研究基金会公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-4284372-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | University of Florida Research Foundation, Incorporated (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-1246858-A | Substituted pyrimidine compounds and their use | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |
| CN-1246857-A | Substituted pyrimidinone and pyridinone compounds and their use | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |
| EP-0974602-A1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR Corporation (JP) | 2000-01-26 | — | — | EP | disclosed |
| CN-1242773-A | Ticyclic carbapenem compound | GLAXO WELLCOME SPA (IT) | 2000-01-26 | — | — | CN | disclosed |
| EP-0948497-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0937078-A1 | TRICYCLIC CARBAPENEM COMPOUNDS | GLAXO WELLCOME S.p.A. (IT) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998024782-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998021210-A1 | TRICYCLIC CARBAPENEM COMPOUNDS | GLAXO WELLCOME S.P.A. (IT) | 1998-05-22 | — | — | WO | disclosed |
| US-4125530-A | FROM 1,1-DIHALO-3,3,3-TRIFLUOROACETONE, BASE, AMMONIA AND A CARBOXALDEHYDE | MERCK & CO., INC. (US) | 1978-11-14 | — | — | US | disclosed |
| US-4032522-A | ANTI-GOUT, ANTI-HYPERURICEMIC | MERCK & CO., INC. (US) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344606-B2 | Next-generation modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | SRC 3006/4885CYP2A6 2313/4885ALDH1A1 4562/4885 |
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | NLN, OAT, PC | SRC 4051/4885CYP2A6 1210/4885ALDH1A1 424/4885 |
| US-12421224-B2 | Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | UGGT1, MAN2A1, MAN2B2 | SRC 2191/4885CYP2A6 544/4885ALDH1A1 405/4885 |
| US-20250313561-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | SRC 3006/4885CYP2A6 2313/4885ALDH1A1 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.